Selected article for: "disease severity and Mexico public hospital"
Author: Lopez-Castaneda, Sandra; García-Larragoiti, Nallely; Cano-Mendez, Alan; Blancas-Ayala, Kenia; Damian-Vázquez, Guadalupe; Perez-Medina, Ana Itzel; Chora-Hernández, Luis David; Arean-Martínez, Carlos; Viveros-Sandoval, Martha Eva
Title: Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection
  • Cord-id: druq0b7e
  • Document date: 2021_4_9
    • ID: druq0b7e
    Snippet: Among COVID-19 hospitalized patients, high incidence of alterations in inflammatory and coagulation biomarkers correlates with a poor prognosis. Comorbidities such as chronic degenerative diseases are frequently associated with complications in COVID-19 patients. The aim of this study was to evaluate inflammatory and procoagulant biomarkers in COVID-19 patients from a public hospital in Mexico. Blood was sampled within the first 48 h after admission in 119 confirmed COVID-19 patients that were c
    Document: Among COVID-19 hospitalized patients, high incidence of alterations in inflammatory and coagulation biomarkers correlates with a poor prognosis. Comorbidities such as chronic degenerative diseases are frequently associated with complications in COVID-19 patients. The aim of this study was to evaluate inflammatory and procoagulant biomarkers in COVID-19 patients from a public hospital in Mexico. Blood was sampled within the first 48 h after admission in 119 confirmed COVID-19 patients that were classified in 3 groups according to oxygen demand, evolution and the severity of the disease as follows: 1) Non severe: nasal cannula or oxygen mask; 2) Severe: high flow nasal cannula and 3) Death: mechanical ventilation eventually leading to fatal outcome. Blood samples from 20 healthy donors were included as a Control Group. Analysis of inflammatory and coagulation biomarkers including D-dimer, interleukin 6, interleukin 8, PAI-1, P-selectin and VWF was performed in plasma. Routine laboratory and clinical biomarkers were also included and compared among groups. Concentrations of D-dimer (14.5 ± 13.8 µg/ml) and PAI-1 (1223 ± 889.6 ng/ml) were significantly elevated in severe COVID-19 patients (P < 0.0001). A significant difference was found in interleukin-6, PAI-1 and P-selectin in non-severe and healthy donors when compared to Severe COVID-19 and deceased patients (P < 0.001). VWF levels were also significantly different between severe patients (153.5 ± 24.3 UI/dl) and non-severe ones (133.9 ± 20.2 UI/dl) (P < 0.0001). WBC and glucose levels were also significantly elevated in patients with Severe COVID-19. Plasma concentrations of all prothrombotic biomarkers were significantly higher in patients with a fatal outcome.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and local release: 1, 2, 3, 4
    • acute respiratory and lung vasculature: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and additional study: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress syndrome and local release: 1
    • acute respiratory distress syndrome and lung vasculature: 1, 2
    • acute respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional study and lymphocyte count: 1, 2, 3
    • lmwh weight heparin and lymphocyte count: 1